vs

Side-by-side financial comparison of CODEXIS, INC. (CDXS) and Gevo, Inc. (GEVO). Click either name above to swap in a different company.

Gevo, Inc. is the larger business by last-quarter revenue ($45.3M vs $38.9M, roughly 1.2× CODEXIS, INC.). CODEXIS, INC. runs the higher net margin — 24.7% vs -13.2%, a 37.9% gap on every dollar of revenue. On growth, Gevo, Inc. posted the faster year-over-year revenue change (695.6% vs 81.3%). CODEXIS, INC. produced more free cash flow last quarter ($19.6M vs $8.7M). Over the past eight quarters, Gevo, Inc.'s revenue compounded faster (237.1% CAGR vs 51.0%).

Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.

Gevo, Inc. is an American renewable chemicals and advanced biofuels company headquartered in unincorporated Douglas County, Colorado, in the Denver-Aurora metropolitan area. Gevo operates in the sustainability sector, pursuing a business model based on the concept of the "circular economy". The company develops bio-based alternatives to petroleum-based products using a combination of biotechnology and classical chemistry. Gevo uses the GREET model from Argonne National Laboratory as a basis f...

CDXS vs GEVO — Head-to-Head

Bigger by revenue
GEVO
GEVO
1.2× larger
GEVO
$45.3M
$38.9M
CDXS
Growing faster (revenue YoY)
GEVO
GEVO
+614.2% gap
GEVO
695.6%
81.3%
CDXS
Higher net margin
CDXS
CDXS
37.9% more per $
CDXS
24.7%
-13.2%
GEVO
More free cash flow
CDXS
CDXS
$10.8M more FCF
CDXS
$19.6M
$8.7M
GEVO
Faster 2-yr revenue CAGR
GEVO
GEVO
Annualised
GEVO
237.1%
51.0%
CDXS

Income Statement — Q4 2025 vs Q4 2025

Metric
CDXS
CDXS
GEVO
GEVO
Revenue
$38.9M
$45.3M
Net Profit
$9.6M
$-6.0M
Gross Margin
94.8%
Operating Margin
27.1%
-4.8%
Net Margin
24.7%
-13.2%
Revenue YoY
81.3%
695.6%
Net Profit YoY
192.5%
65.9%
EPS (diluted)
$0.13
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDXS
CDXS
GEVO
GEVO
Q4 25
$38.9M
$45.3M
Q3 25
$8.6M
$42.7M
Q2 25
$15.3M
$43.4M
Q1 25
$7.5M
$29.1M
Q4 24
$21.5M
$5.7M
Q3 24
$12.8M
$2.0M
Q2 24
$8.0M
$5.3M
Q1 24
$17.1M
$4.0M
Net Profit
CDXS
CDXS
GEVO
GEVO
Q4 25
$9.6M
$-6.0M
Q3 25
$-19.6M
$-8.0M
Q2 25
$-13.3M
$2.1M
Q1 25
$-20.7M
$-21.7M
Q4 24
$-10.4M
$-17.6M
Q3 24
$-20.6M
$-21.2M
Q2 24
$-22.8M
$-21.0M
Q1 24
$-11.5M
$-18.9M
Gross Margin
CDXS
CDXS
GEVO
GEVO
Q4 25
94.8%
Q3 25
71.3%
Q2 25
86.3%
Q1 25
63.8%
Q4 24
83.0%
Q3 24
66.4%
Q2 24
56.6%
Q1 24
71.6%
Operating Margin
CDXS
CDXS
GEVO
GEVO
Q4 25
27.1%
-4.8%
Q3 25
-220.3%
-8.6%
Q2 25
-83.9%
13.4%
Q1 25
-271.6%
-69.2%
Q4 24
-34.2%
-344.7%
Q3 24
-129.0%
-1221.8%
Q2 24
-284.9%
-456.8%
Q1 24
-69.6%
-580.0%
Net Margin
CDXS
CDXS
GEVO
GEVO
Q4 25
24.7%
-13.2%
Q3 25
-228.1%
-18.6%
Q2 25
-86.6%
4.9%
Q1 25
-274.3%
-74.6%
Q4 24
-48.4%
-308.9%
Q3 24
-160.8%
-1076.6%
Q2 24
-285.2%
-399.3%
Q1 24
-67.4%
-473.1%
EPS (diluted)
CDXS
CDXS
GEVO
GEVO
Q4 25
$0.13
$-0.03
Q3 25
$-0.22
$-0.03
Q2 25
$-0.16
$0.01
Q1 25
$-0.25
$-0.09
Q4 24
$-0.12
$-0.08
Q3 24
$-0.29
$-0.09
Q2 24
$-0.32
$-0.09
Q1 24
$-0.16
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDXS
CDXS
GEVO
GEVO
Cash + ST InvestmentsLiquidity on hand
$78.2M
$81.2M
Total DebtLower is stronger
$40.1M
$164.8M
Stockholders' EquityBook value
$50.5M
$466.3M
Total Assets
$147.8M
$718.9M
Debt / EquityLower = less leverage
0.79×
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDXS
CDXS
GEVO
GEVO
Q4 25
$78.2M
$81.2M
Q3 25
$58.7M
$72.6M
Q2 25
$66.3M
$57.3M
Q1 25
$59.8M
$65.3M
Q4 24
$73.5M
$189.4M
Q3 24
$90.3M
$223.2M
Q2 24
$73.2M
$245.7M
Q1 24
$85.5M
$270.6M
Total Debt
CDXS
CDXS
GEVO
GEVO
Q4 25
$40.1M
$164.8M
Q3 25
$39.7M
$164.5M
Q2 25
$39.4M
$167.5M
Q1 25
$29.2M
$167.0M
Q4 24
$28.9M
$67.1M
Q3 24
$28.6M
$67.0M
Q2 24
$28.4M
$66.8M
Q1 24
$28.1M
$68.3M
Stockholders' Equity
CDXS
CDXS
GEVO
GEVO
Q4 25
$50.5M
$466.3M
Q3 25
$38.5M
$468.9M
Q2 25
$55.6M
$474.1M
Q1 25
$49.6M
$469.8M
Q4 24
$66.9M
$489.5M
Q3 24
$73.4M
$504.7M
Q2 24
$61.4M
$522.7M
Q1 24
$79.3M
$541.9M
Total Assets
CDXS
CDXS
GEVO
GEVO
Q4 25
$147.8M
$718.9M
Q3 25
$124.0M
$685.2M
Q2 25
$138.2M
$702.1M
Q1 25
$128.9M
$677.8M
Q4 24
$149.0M
$583.9M
Q3 24
$148.2M
$583.9M
Q2 24
$132.0M
$617.9M
Q1 24
$149.6M
$633.6M
Debt / Equity
CDXS
CDXS
GEVO
GEVO
Q4 25
0.79×
0.35×
Q3 25
1.03×
0.35×
Q2 25
0.71×
0.35×
Q1 25
0.59×
0.36×
Q4 24
0.43×
0.14×
Q3 24
0.39×
0.13×
Q2 24
0.46×
0.13×
Q1 24
0.35×
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDXS
CDXS
GEVO
GEVO
Operating Cash FlowLast quarter
$20.1M
$20.0M
Free Cash FlowOCF − Capex
$19.6M
$8.7M
FCF MarginFCF / Revenue
50.3%
19.3%
Capex IntensityCapex / Revenue
1.3%
24.7%
Cash ConversionOCF / Net Profit
2.09×
TTM Free Cash FlowTrailing 4 quarters
$-23.8M
$-43.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDXS
CDXS
GEVO
GEVO
Q4 25
$20.1M
$20.0M
Q3 25
$-7.7M
$-6.8M
Q2 25
$-18.0M
$-2.5M
Q1 25
$-13.8M
$-24.0M
Q4 24
$-16.5M
$-18.8M
Q3 24
$-13.0M
$-11.0M
Q2 24
$-12.2M
$-11.4M
Q1 24
$-7.8M
$-16.1M
Free Cash Flow
CDXS
CDXS
GEVO
GEVO
Q4 25
$19.6M
$8.7M
Q3 25
$-7.9M
$-14.6M
Q2 25
$-20.5M
$-7.8M
Q1 25
$-15.1M
$-29.9M
Q4 24
$-18.2M
$-33.5M
Q3 24
$-14.0M
$-20.8M
Q2 24
$-12.6M
$-20.6M
Q1 24
$-8.9M
$-33.6M
FCF Margin
CDXS
CDXS
GEVO
GEVO
Q4 25
50.3%
19.3%
Q3 25
-91.7%
-34.2%
Q2 25
-133.6%
-17.9%
Q1 25
-199.6%
-102.7%
Q4 24
-85.0%
-587.2%
Q3 24
-109.0%
-1057.0%
Q2 24
-157.5%
-392.4%
Q1 24
-52.2%
-841.9%
Capex Intensity
CDXS
CDXS
GEVO
GEVO
Q4 25
1.3%
24.7%
Q3 25
2.1%
18.3%
Q2 25
16.4%
12.1%
Q1 25
16.7%
20.0%
Q4 24
8.3%
256.6%
Q3 24
7.8%
496.2%
Q2 24
5.0%
174.8%
Q1 24
6.6%
438.9%
Cash Conversion
CDXS
CDXS
GEVO
GEVO
Q4 25
2.09×
Q3 25
Q2 25
-1.18×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons